Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ACSL1 | P33121 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25307709 | 1.00 | DGAT1 (0.44) | DGAT1SOAT1KCNH2KMOHSD11B1 | |
| SCHEMBL22576465 | 0.86 | MALT1 (0.39) | KMO | |
| SCHEMBL29438247 | 0.85 | SMN1; SMN2 (0.40) | DGAT1SOAT1KCNH2KMOHSD11B1 | |
| SCHEMBL21525573 | 0.84 | DGAT1 (0.44) | DGAT1SOAT1KCNH2HSD11B1ACSL1 | |
| SCHEMBL23582445 | 0.84 | DGAT1 (0.42) | DGAT1SOAT1KCNH2HSD11B1ACSL1 | |
| SCHEMBL21525572 | 0.84 | DGAT1 (0.44) | DGAT1SOAT1KCNH2HSD11B1ACSL1 | |
| SCHEMBL23582299 | 0.84 | DGAT1 (0.42) | DGAT1SOAT1KCNH2HSD11B1ACSL1 | |
| SCHEMBL23582298 | 0.84 | DGAT1 (0.42) | DGAT1SOAT1KCNH2HSD11B1ACSL1 | |
| SCHEMBL23582472 | 0.82 | CYP2C19 (0.46) | DGAT1HSD11B1 | |
| SCHEMBL8515150 | 0.80 | EPHX2 (0.41) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4206193-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | DGAT2, DGAT1, MOGAT2 | DGAT1 2/4885SOAT1 15/4885KCNH2 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.